Repligen Corp (RGEN) Reports Robust Q2 2026 Performance and Upgrades Full‑Year Guidance

Repligen Corporation, a Nasdaq‑listed bioprocessing specialist, surpassed consensus estimates in the second quarter of 2026, driving a 3 % rally in early trading on July 28 and a 16 % spike later in the day. The company posted a non‑GAAP earnings per share of $0.54 versus the $0.45 consensus, and reported revenue of $204.1 million, an 11.9 % increase year‑over‑year and above expectations.

Revenue Drivers

The company highlighted Proteins and Process Analytics as the primary growth engines. Revenue from China rose 60 % YoY, while capital‑equipment sales in the first half of 2026 climbed in the high‑single digits. APAC overall contributed a significant share of the growth, underscoring Repligen’s expanding footprint in high‑growth markets.

Updated Guidance

In response to the strong quarterly results, Repligen raised its full‑year revenue outlook to $824 million (up from $813‑$834 million previously) and lifted adjusted earnings per share to a range of $2.03 – $2.09. The company’s updated forecast signals confidence that it is achieving growth well above the broader bioprocessing market.

Analyst Sentiment

  • J.P. Morgan analyst Casey Woodring upgraded his price target from $165 to $175, reflecting the company’s improved trajectory.
  • Canaccord Genuity’s Kyle Mikson maintained a Hold rating and a $145 price target, noting that the 2026 guidance demonstrates execution of its growth strategy.
  • TipRanks reports a Strong Buy consensus, with 11 Buy and 3 Hold ratings, citing the “market‑leading” Q2 figures.

Market Context

With a market capitalization of $7.4 billion and a price‑to‑earnings ratio of 143.86, Repligen sits within a sector that continues to attract significant capital as biopharmaceutical manufacturing demands intensify. The recent earnings beat, coupled with the guidance upgrade, suggests that the market is recognizing Repligen’s ability to deliver incremental value to its customers—life‑science firms, global biopharmaceuticals, and contract manufacturers worldwide.

Forward Outlook

Repligen’s focus on protein manufacturing and process analytics positions it to capitalize on the ongoing shift toward biologics and personalized medicine. The company’s expansion in China and other APAC territories, coupled with the projected revenue growth, points to a trajectory that could sustain the upward revision of earnings guidance into the next fiscal year. Investors and analysts alike will watch how Repligen maintains its momentum and leverages its technology portfolio to secure long‑term market leadership in bioprocessing.